Cerus Co. (NASDAQ:CERS) CFO Kevin Dennis Green Sells 60,656 Shares

Cerus Co. (NASDAQ:CERS) CFO Kevin Dennis Green sold 60,656 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $1.58, for a total value of $95,836.48. Following the completion of the sale, the chief financial officer now owns 493,862 shares of the company’s stock, valued at approximately $780,301.96. This trade represents a 10.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Cerus Stock Up 1.9 %

NASDAQ CERS opened at $1.61 on Thursday. The business has a fifty day moving average price of $1.74 and a two-hundred day moving average price of $1.80. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. Cerus Co. has a fifty-two week low of $1.38 and a fifty-two week high of $2.59. The stock has a market capitalization of $299.12 million, a PE ratio of -14.64 and a beta of 1.29.

Cerus (NASDAQ:CERS) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. The firm had revenue of $50.81 million during the quarter, compared to analysts’ expectations of $50.81 million. Equities analysts expect that Cerus Co. will post -0.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $4.00 price target on shares of Cerus in a research note on Friday, February 21st.

Institutional Investors Weigh In On Cerus

Several institutional investors and hedge funds have recently added to or reduced their stakes in CERS. Squarepoint Ops LLC increased its holdings in shares of Cerus by 2,084.7% during the fourth quarter. Squarepoint Ops LLC now owns 492,732 shares of the biotechnology company’s stock worth $759,000 after buying an additional 470,178 shares in the last quarter. Two Sigma Advisers LP increased its holdings in shares of Cerus by 249.5% during the fourth quarter. Two Sigma Advisers LP now owns 254,100 shares of the biotechnology company’s stock worth $391,000 after buying an additional 181,400 shares in the last quarter. Two Sigma Investments LP increased its holdings in shares of Cerus by 121.6% during the fourth quarter. Two Sigma Investments LP now owns 595,234 shares of the biotechnology company’s stock worth $917,000 after buying an additional 326,605 shares in the last quarter. State of Wyoming increased its holdings in shares of Cerus by 39.1% during the fourth quarter. State of Wyoming now owns 129,840 shares of the biotechnology company’s stock worth $200,000 after buying an additional 36,488 shares in the last quarter. Finally, ProShare Advisors LLC increased its holdings in shares of Cerus by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 50,817 shares of the biotechnology company’s stock worth $78,000 after buying an additional 16,720 shares in the last quarter. 78.37% of the stock is currently owned by institutional investors.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.